Fc receptor protein collection
Recombinant Fc Receptor proteins from AMSBIO are uniquely suitable for pharmaceutical research.
AMSBIO announces an extensive collection of recombinant Fc receptor proteins, including their common variants, to help accelerate the development of therapeutic monoclonal antibodies (mAb).
Therapeutic antibody efficacy depends not only on the Fab fragment and its binding activity to the target antigen, but also depends on the Fc fragment and its interaction with key Fc receptors. As a consequence screening for desired binding affinity to the key Fc receptors is an essential component in the development of a high quality therapeutic mAb.
Recombinant Fc Receptor proteins from AMSBIO are uniquely suitable for pharmaceutical research. All proteins are analysed by SDS-PAGE and HPLC to guarantee their high purity/quality and supplied binding quality validated by both Surface Plasmon Resonance and ELISA. Being expressed in HEK293 cells these recombinant Fc Receptor proteins retain their authentic post-translational processing leading to high bioactivity and stability.
The proteins are also available in a ready-to-use biotinylated format that makes assay development much faster and easier. The biotin-labelled proteins from AMSBIO are produced using proprietary in-house labelling techniques, which maintains the high bioactivity and avoids batch-to-batch variation.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.